Zenalpha
Active substance
ATC code
Species
Dogs.
Indications
To provide restraint, sedation and analgesia during conduct of non-invasive, nonpainful or mildly painful procedures and examinations intended to last no more than 30 minutes.
Dose to be administered and administration route
For intramuscular use.
The dose is based on body surface area. The dose will result in administration of 1 mg medetomidine and 20 mg vatinoxan per square metre of body surface area (m2).
Calculate the dose using 1 mg/m2 medetomidine or use the dosing table below. Note that the mg/kg dosage decreases as body weight increases.
Use of an appropriately graduated syringe is recommended to ensure accurate dosing when administering small volumes.
To ensure a correct dosage, bodyweight should be determined as accurately as possible.
Table 1. Dose volume based on bodyweight
Dog bodyweight | Dose volume |
kg | ml |
3.5 to 4 | 0.4 |
4.1 to 5 | 0.6 |
5.1 to 7 | 0.7 |
7.1 to 10 | 0.8 |
10.1 to 13 | 1.0 |
13.1 to 15 | 1.2 |
15.1 to 20 | 1.4 |
20.1 to 25 | 1.6 |
25.1 to 30 | 1.8 |
30.1 to 33 | 2.0 |
33.1 to 37 | 2.2 |
37.1 to 45 | 2.4 |
45.1 to 50 | 2.6 |
50.1 to 55 | 2.8 |
55.1 to 60 | 3.0 |
60.1 to 65 | 3.2 |
65.1 to 70 | 3.4 |
70.1 to 80 | 3.6 |
>80 | 3.8 |
Re-administration of the veterinary medicinal product during the same procedure has not been evaluated and therefore the veterinary medicinal product should not be readministered during the same procedure.
The number of permissible stopper broachings is limited to a maximum of 15.
Adverse reactions
Hypothermia, bradycardia and tachycardia were very commonly observed in safety and clinical studies. Diarrhoea/colitis and muscle tremor were commonly observed. Vomiting/nausea and involuntary defaecation were uncommonly observed. Cardiac arrhythmias, such as second-degree AV block and ventricular escape complexes, were seen very commonly in laboratory safety studies. Injected sclera were observed very rarely in laboratory safety studies.
All of the above adverse reactions were transient/resolved without treatment, although external warming was provided where required in cases of hypothermia.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 42810/5000 |
| EAN | 5701170442700 |
